Comparative Pharmacology
Head-to-head clinical analysis: DEMADEX versus FUROSEMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMADEX versus FUROSEMIDE.
DEMADEX vs FUROSEMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium ions, leading to increased urine output.
Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.
Adults: 20-80 mg orally once or twice daily; IV/IM: 20-40 mg once or twice daily, may increase by 20-40 mg every 6-8 hours. Max dose: 600 mg/day.
None Documented
None Documented
Clinical Note
moderateFurosemide + Digoxin
"The risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin."
Clinical Note
moderateFurosemide + Digitoxin
"The risk or severity of adverse effects can be increased when Furosemide is combined with Digitoxin."
Clinical Note
moderateFurosemide + Deslanoside
"The risk or severity of adverse effects can be increased when Furosemide is combined with Deslanoside."
Clinical Note
moderateFurosemide + Acetyldigitoxin
The terminal elimination half-life is approximately 4 hours (range 2-8 hours) in patients with normal renal function. In renal impairment (creatinine clearance <30 mL/min), half-life is prolonged to 10-12 hours due to reduced renal clearance. In hepatic cirrhosis, half-life may be extended to 8-9 hours due to decreased metabolism.
0.5-2 hours (terminal); prolonged in renal impairment (up to 9-24 hours) and hepatic cirrhosis (up to 2-4 hours).
Approximately 50% of the absorbed dose is excreted unchanged in the urine via glomerular filtration and active tubular secretion. The remainder undergoes hepatic metabolism to glucuronide conjugates and minor oxidative metabolites, with biliary excretion of metabolites (about 30-40% of the dose) eliminated in feces. Renal clearance is the primary route for the parent drug.
Renal (50-80% unchanged; remainder as glucuronide metabolite); fecal (<2%).
Category C
Category A/B
Loop Diuretic
Loop Diuretic
"The risk or severity of adverse effects can be increased when Furosemide is combined with Acetyldigitoxin."